Thus, we aimed to evaluate the therapeutic utility of HDACi in controlling Pa-LPS induced neutrophilic lung inflammation in CF-preclinical murine models (Cftr+/+ and Cftr−/− mice). The gene discussed is CFTR; the disease is cystic fibrosis.